Novo Nordisk (NVO) Stock: Novo Goes to Court to Silence Lilly’s Weight-Loss Ads
TLDR
- Novo Nordisk filed a motion for a preliminary injunction to immediately halt Eli Lilly’s obesity and diabetes drug ads in the U.S.
- Novo claims Lilly’s ads for Zepbound and Mounjaro used misleading dose comparisons against Wegovy and Ozempic.
- The lawsuit alleges Lilly omitted newer, higher-dose versions of Novo’s drugs that deliver greater weight loss.
- Novo is seeking a permanent injunction and corrective advertising from Lilly.
- Lilly has denied wrongdoing and says it will vigorously defend itself.
Novo Nordisk filed a motion Friday for a preliminary injunction in the U.S. District Court for the District of New Jersey, asking a judge to immediately stop Eli Lilly from running its current obesity and diabetes drug advertising campaigns.
NVO stock was down 0.02% on the day, while LLY gained 1.97%.
The move is the latest step in a legal battle Novo kicked off on Tuesday when it filed a lawsuit against Lilly.
Novo had warned at the time that it would seek an emergency court order if Lilly did not voluntarily pull the disputed ads. Lilly did not.
… Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
